Tevi Troy

And this is part of a 30-plus year war that I talk about in Commentary Magazine. where the trial lawyers and Hollywood and the Democratic Party and now, unfortunately, the Republican Party are constantly demonizing Big Pharma, imposing new restrictions on them, doing new lawsuits on them, making them the bad guys in all the movies. And that makes them unpopular.

It makes their products more expensive. And it also makes it less likely that young, smart Americans are going to go into the pharmaceutical industry and innovate and create great new products.

It makes their products more expensive. And it also makes it less likely that young, smart Americans are going to go into the pharmaceutical industry and innovate and create great new products.

It makes their products more expensive. And it also makes it less likely that young, smart Americans are going to go into the pharmaceutical industry and innovate and create great new products.

The best year we've ever had was the FDA approving about 50 products in one year. Usually it's closer to about 30 products in a year. And just think about all the companies and all the potential products and all the potential sicknesses and illnesses that can be treated. So it's very hard. It is a huge winnowing process. And also this gets into your expertise, Ben, about Hollywood and the culture.

The best year we've ever had was the FDA approving about 50 products in one year. Usually it's closer to about 30 products in a year. And just think about all the companies and all the potential products and all the potential sicknesses and illnesses that can be treated. So it's very hard. It is a huge winnowing process. And also this gets into your expertise, Ben, about Hollywood and the culture.

The best year we've ever had was the FDA approving about 50 products in one year. Usually it's closer to about 30 products in a year. And just think about all the companies and all the potential products and all the potential sicknesses and illnesses that can be treated. So it's very hard. It is a huge winnowing process. And also this gets into your expertise, Ben, about Hollywood and the culture.

It creates this blockbuster effect where you don't want to do a single or a double. Every drug has to be a home run in order to justify the massive costs. So that's why every drug they put out is the equivalent of a Marvel movie. And if you do have a small disease called an orphan disease, the drug companies barely even bother to make products for those types of illnesses.

It creates this blockbuster effect where you don't want to do a single or a double. Every drug has to be a home run in order to justify the massive costs. So that's why every drug they put out is the equivalent of a Marvel movie. And if you do have a small disease called an orphan disease, the drug companies barely even bother to make products for those types of illnesses.

It creates this blockbuster effect where you don't want to do a single or a double. Every drug has to be a home run in order to justify the massive costs. So that's why every drug they put out is the equivalent of a Marvel movie. And if you do have a small disease called an orphan disease, the drug companies barely even bother to make products for those types of illnesses.

I think it's about 15 years, but that counts once you declare the patent and it doesn't count all the FDA testing. So there's a whole bunch of things that are happening while your patent clock is ticking. And once that clock ticks down, then as you say, the generic is out there on the market and undercutting you on price. And I'm for generics.

I think it's about 15 years, but that counts once you declare the patent and it doesn't count all the FDA testing. So there's a whole bunch of things that are happening while your patent clock is ticking. And once that clock ticks down, then as you say, the generic is out there on the market and undercutting you on price. And I'm for generics.

I think it's about 15 years, but that counts once you declare the patent and it doesn't count all the FDA testing. So there's a whole bunch of things that are happening while your patent clock is ticking. And once that clock ticks down, then as you say, the generic is out there on the market and undercutting you on price. And I'm for generics.

I think we should have generics after the patent window expires, but it does make it put a lot of pressure on the pharmaceutical companies to get as much to recoup their investment in the period in which they have the patent still in effect.

I think we should have generics after the patent window expires, but it does make it put a lot of pressure on the pharmaceutical companies to get as much to recoup their investment in the period in which they have the patent still in effect.

I think we should have generics after the patent window expires, but it does make it put a lot of pressure on the pharmaceutical companies to get as much to recoup their investment in the period in which they have the patent still in effect.

Yeah, that's exactly right. We are going to see less innovation, fewer products making it to market, maybe fewer markets, or maybe fewer products being available in America. That's what happened in Europe. Europe, because of their price controls, yes, there are lower prices, but they have fewer products available and they have a much less robust biotechnology sector.

Yeah, that's exactly right. We are going to see less innovation, fewer products making it to market, maybe fewer markets, or maybe fewer products being available in America. That's what happened in Europe. Europe, because of their price controls, yes, there are lower prices, but they have fewer products available and they have a much less robust biotechnology sector.

Yeah, that's exactly right. We are going to see less innovation, fewer products making it to market, maybe fewer markets, or maybe fewer products being available in America. That's what happened in Europe. Europe, because of their price controls, yes, there are lower prices, but they have fewer products available and they have a much less robust biotechnology sector.

So there are advantages to our more free market way of pricing, even though the prices are higher here. I do fear that President Trump's executive order is more just a statement than something that actually will change prices. And you would need congressional action.